P. Voorheis, MD, T.G. Paul, MD, J. Nadeau, MD,	R. Mason, MD, H.S. Good, MD, C. Morrison,	MD, C. Guest, MD, D. Schemmer, MD, M. Baerlocher, MD, R. Gr	over, MD, N. Lougheed, MD
GEORGIAN RADIOLOG www.georgianradiology.c	s [] \ s [] [] com [] [BONE MINERAL D Wasaga - 14 Ramblewood Dr. Suite 10 nnisfil - 7325 Yonge St., Suite 1300 Barrie - 11 Lakeside Terrace, Suite LLO	05 (705) 422.2255 (705) 431.5641 1 (705) 722.8036
BOOKING PHONE # :70	5- 726 - 7442	BOOKING FAX # : 705	- 726- 8056
PATIENT Appointme	nt: Booked appt only	(Equipment has a 350	lb weight capacity)
Date: DM_	Y	Time:	am / pm
PREPARATION: Please reschedule your a study less than 2 weeks prior to your app eliminate the need to change into a gow	ppointment if you have had a Nucl ointment. Dress in comfortable cl n. Do not take calcium supplemer	ear Medicine, MRI, CT or X-Ray with contrast less othing without metal : no belts, zippers or bra an its the day of your appointment.	than 1 week prior or a Barium d no navel jewelry. This will
Baseline (1st ever in Ontario)			
Patients with any of the followi	ng risk factors (check Al	L that apply):	
□ Female or Male age ≥ 65		$\square Menopausal female (\ge 1 year post cessation of user structure in the s$	
 History of fragility fracture (after age 40)¹ Recent prolonged glucocorticoid use² 		menstrual periods) with body weight < 60 kg	
□ Recent prolonged glucocorticoid use ² □ Male age $50-64$ with body weight < 60 kg □ Other high risk medication use ³		weight < 60 kg	
Conditions associated wit		SPECIFY:	
Low Risk Follow Up		PLEASE ATTACH PREVIO	DUS REPORT
For patients at LOW fracture ris	k on prior exam, OHIP will	cover:	
A second BMD test 3 YEAI			
A successive BMD test (i.e			
Date Last Exam (Day		 ODERATE or HIGH risk patients (including those rec	
	s reaks are appropriate for most w	ODERATE OF HIGH TISK patients (including those rec	Comments:
High Risk Follow Up			connents.
2-3 year follow up with prev	ious Moderate to High Ris	k BMD without changes to risk level	
 1 year follow up -for any patient, follow up Bi Has a new fragility fract Active risk factor for boi Significant bone loss on Initiated or changed to 	ure ¹ ne loss ^{2,3,4} prior BMD exam ⁶	cation within the past year	REV. Dec 2021
 ²≥3 months in the prior year at a prednisor ³ e.g. aromatase inhibitors, androgen depri ⁴ e.g. primary hyperparathyroidism, osteog or malabsorption syndrome, chronic liver 	The equivalent dose \geq 7.5 mg daily vation therapy, anticonvulsant the enesis imperfecta, uncontrolled hy disease and inflammatory condition	ntified on X- ray or after minor trauma such as a fall from	n standing height or less, lisease, chronic malnutrition atoid arthritis)
* OHIP defines significant bone loss as beir PATIENT INFC		TECH NOT	
DATE: DMYM / F			_3.
Name:		Dractitionar SICN/	ATURE:
Address:			Signature :
		—	: Printed Name
Home P#:	Cell P#:	_	: Fax #

Please bring this form & health card to your examination to avoid delay or cancellation